Regeneron Pharmaceuticals
The Associate Director will lead companion diagnostic (CDx) strategy and development, overseeing programs from biomarker feasibility through clinical validation, regulatory submission, and launch. The role bridges translational science, clinical development, regulatory affairs, and external IVD partners to deliver fit‑for‑purpose assays that support drug development decisions.
Headquarters
Tarrytown, New York, United States
Company Size
10001+ employees
Founded
1988
Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.
Quadrant Capital Group LLC Purchases 1,564 Shares of Regeneron Pharmaceuticals, Inc. $REGN
4 hours ago
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
6 hours ago
Will Positive Obesity Data and Dupixent Expansion Efforts Change Regeneron Pharmaceuticals' (REGN) Narrative?
1 day ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Regeneron Pharmaceuticals.
11% above the average for this role
Regeneron: Fairly Valued Now After A Stellar Upswing (NASDAQ:REGN)
1 day ago
Translational Biomarker and CDx Leader
Pierre Fabre Group
Director, Regulatory Affairs Companion Diagnostics
Revolution Medicines
Senior Manager, Biomarker Development
Tango Therapeutics
Senior Director of Translational Medicine
Eikon Therapeutics
Senior Director Diagnostic Assays/Cancer Biomarker Development
AstraZeneca
Scientist/Senior Scientist, Clinical Pathology & IHC
Systimmune